Articles related to NEUROMUSCULAR DISORDERS

HyQvia, now FDA-approved for CIDP, shows a significant reduction in relapse rates, presenting an effective subcutaneous alternative to IVIG infusions.

It is especially important to educate physicians who provide primary care to patients of these ages about spinal muscular atrophy (SMA) and other neuromuscular diseases. Shortening diagnostic times is critical for the success of current therapies, and neonatal SMA screening programs have a high potential for identifying affected children.

The studies described in Acta Neurologica Belgica assess eight patients who developed a new-onset neuromuscular disorder following COVID-19 vaccination. “These various presentations strengthen the association between COVID-19 vaccination and particular GBS phenotypes,” the researchers noted.